• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method

    5/28/25 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELUT alert in real time by email

    SILVER SPRING, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a peer-reviewed article describing the first validated method for measuring antibiotic release from a biologic envelope. The novel method demonstrates in vitro elution that closely replicates preclinical studies, offering an approach to characterize drug release while enabling faster, lower cost development and testing of the EluPro portfolio. The article appears in the current issue of Dissolution Technologies.

    Drug release testing is a critical element of product development and regulatory evaluation for combination products, which integrate drugs and devices. The U.S. Food and Drug Administration (FDA) considers drug elution performance essential for establishing manufacturing consistency and control. Elutia's new method delivers reliable data in 30 hours—for results comparable to 14-day in vivo protocols—allowing for faster iteration and lower resource usage. It captures the biphasic release profile of minocycline and rifampin, including both the immediate and sustained release phases.

    "This work reflects Elutia's leadership in developing high-performing drug-eluting biomatrices grounded in rigorous science," said Dana Yoo, Ph.D., Vice President of Development at Elutia. "Having a robust, validated in vitro method supports the product lifecycle for EluPro—the first and only FDA-cleared antibiotic-eluting bioenvelope—and accelerates the development of future drug-eluting biologic matrices in our pipeline."

    EluPro, an antibiotic-eluting bioenvelope designed for use with cardiac implantable electronic devices (CIEDs) and neurostimulators, was commercially launched in the United States in January 2025. Its unique combination of trusted antibiotics and a soft, regenerative biomatrix supports healing while naturally conforming to pocket anatomy and the cardiac implant, addressing device-related complications. The antibiotic-eluting disc delivers consistent and reproducible drug release, providing local drug delivery without compromising the biomatrix's regenerative properties.

    To learn more, visit www.elutia.com/products/elupro/.

    About Elutia

    Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia's mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

    Forward Looking Statements

    This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including any statements and information concerning the market reception of EluPro, including the timing and anticipated success thereof, and the development, testing and anticipated success of the EluPro portfolio. These forward-looking statements are based on our management's beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: our ability to successfully commercialize, market and sell our EluPro product; our ability to continue as a going concern; our ability to achieve or sustain profitability; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits and claims related to our recalled FiberCel and other viable bone matrix products and avoid a material adverse financial consequence from those lawsuits and claims; our ability to prevail in lawsuits and claims seeking indemnity, contribution and insurance coverage for FiberCel and other viable bone matrix product liabilities; the continued and future acceptance of our products by the medical community; our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings; our dependence on our commercial partners and independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; our ability to successfully realize the anticipated benefits of the November 2023 sale of our Orthobiologics business; physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations that could adversely affect our sales and profitability; our ability to obtain regulatory approval or other marketing authorizations by the FDA and comparable foreign authorities for our products and product candidates; our ability to obtain, maintain and adequately protect our intellectual property rights; and other important factors which can be found in the "Risk Factors" section of Elutia's public filings with the Securities and Exchange Commission ("SEC"), including Elutia's Annual Report on Form 10-K for the year ended December 31, 2024, as such factors may be updated from time to time in Elutia's other filings with the SEC, including Elutia's Quarterly Reports on Form 10-Q, accessible on the SEC's website at www.sec.gov and the Investor Relations page of Elutia's website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    Investors:

    Matt Steinberg

    FINN Partners

    [email protected]

    This press release was published by a CLEAR® Verified individual.



    Primary Logo

    Get the next $ELUT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELUT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELUT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method

      SILVER SPRING, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a peer-reviewed article describing the first validated method for measuring antibiotic release from a biologic envelope. The novel method demonstrates in vitro elution that closely replicates preclinical studies, offering an approach to characterize drug release while enabling faster, lower cost development and testing of the EluPro portfolio. The article appears in the current issue of Dissolution Technologies. Drug release testing is a critical element of product development and regulatory evaluat

      5/28/25 8:00:00 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales

      - New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m. PT - SILVER SPRING, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today reported strong first-quarter results for 2025 and highlighted key developments driving the adoption of EluPro™. In its first quarter post-launch, EluPro demonstrated strong momentum, establishing its position as a groundbreaking solution for cardiac implantable electronic device (CIED) procedures. Business Highlights: The EluPro™ Revolution is Now Underway: In its first full quarter post-launch, EluPro e

      5/8/25 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

      Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today announced it is reclaiming U.S. sales and distribution responsibilities for its cardiovascular portfolio—including ProxiCor®, VasCure®, and Tyke®—following the conclusion of its distribution agreement with LeMaitre Vascular, Inc. The move allows Elutia to directly capture top-line revenue and should improve the gross margin and profitability of this product segment. Elutia has appointed Dwayne Montgomery as Head of Cardiovascular to lead this newly establish

      5/1/25 4:05:06 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Financials

    Live finance-specific insights

    See more

    $ELUT
    SEC Filings

    See more

    $ELUT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ELUT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ELUT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ELUT
    Leadership Updates

    Live Leadership Updates

    See more
    • Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

      SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13753035 Please log in approximately 10 minutes prior to the scheduled start time. A liv

      5/1/25 8:00:00 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

      SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13751810 Please log in approximately 10 minutes prior to the scheduled

      2/20/25 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

      Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024. Business Highlights: First Commercial Use: Announced the first patient implant of EluPro, the FDA-cleared antibiotic-eluting biologic envelope for pacemakers and neurostimulators.Strong Initial Adoption: EluPro is being utilized across all major cardiac implantable electronic device (CIED) brands and in neurostimulation procedures. EluPro now accounts

      11/14/24 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elutia Inc.

      SCHEDULE 13G/A - ELUTIA INC. (0001708527) (Subject)

      5/15/25 4:49:05 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Elutia Inc.

      SCHEDULE 13G - ELUTIA INC. (0001708527) (Subject)

      5/15/25 4:25:26 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Elutia Inc.

      10-Q - ELUTIA INC. (0001708527) (Filer)

      5/13/25 4:50:30 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:30:13 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:28:27 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Birchview Capital, Lp bought $206,958 worth of shares (140,000 units at $1.48) (SEC Form 4) (Amendment)

      4/A - ELUTIA INC. (0001708527) (Issuer)

      2/20/24 12:27:11 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:30:13 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:28:27 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF FINANCIAL OFFICER Ferguson Matthew converted options into 30,287 shares and covered exercise/tax liability with 12,413 shares, increasing direct ownership by 7% to 342,378 units (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/11/25 5:54:33 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Elutia Inc.

      SC 13G - ELUTIA INC. (0001708527) (Subject)

      10/15/24 6:59:31 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Elutia Inc. (Amendment)

      SC 13G/A - ELUTIA INC. (0001708527) (Subject)

      2/20/24 12:03:03 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

      SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries. "We are pleased to welcome Ryan to the Elutia CRU as our new Vice President of Operations," said Dr. Randy Mills, Elutia's Chief Executive Officer. "At Elutia, culture matters, and Ryan has both the experience and character to make him an excellent fit and an effectiv

      7/31/24 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care